Sector Gamma AS’s Denali Therapeutics DNLI Stock Holding History

Sector Gamma AS’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-162,710	Closed	-$3.12M	–	44
2026 Q1	$3.12M	Buy	+162,710	New	+$3.24M	0.74%	38

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sector Gamma AS's DNLI Position: Q2 2026 in Review

Sector Gamma AS sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 162,710 shares — an estimated $3.12M sold.

Sector Gamma AS first reported a position in DNLI in Q1 2026 and held it in 1 quarter. The position peaked at $3.12M in Q1 2026. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Sector Gamma AS reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
Sector Gamma AS sold 162,710 Denali Therapeutics shares in Q2 2026, an estimated $3.12M.
Sector Gamma AS first reported a position in Denali Therapeutics in Q1 2026 and held it in 1 quarter.
Sector Gamma AS's Denali Therapeutics position peaked at $3.12M in Q1 2026.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Sector Gamma AS's 13F filing for Q2 2026, filed 12 Aug 2026.